Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it has submitted a Biologics License ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...

REGENXBIO Inc. highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year for REGENXBIO, ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Applic ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

TAIPEI, TW, Jan 12, 2026 - (ACN Newswire) - OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based ...

Ash Hewson is CEO of Affinity, part of Canva. When I announced at Canva World Tour in October that the all-new, professional-grade Affinity would become completely free, the design world reacted with ...

(Bloomberg) --Jared Kushner’s Affinity Partners is exiting the takeover battle for Warner Bros. Discovery Inc. in a political and financial blow to a foundering hostile takeover bid for the fabled ...

Validated clinical efficacy and scalable manufacturing propel exosomes from research discovery to commercial therapeutics.

Agency leaders share how emotion shapes trust, loyalty and long-term impact, revealing why the way brands make people feel ...